Incorporating financial toxicity considerations into clinical trial design to facilitate patient‐centered decision‐making in oncology
Cancer · 2023
DOI: 10.1002/cncr.34677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Laila A Gharzai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Financial Stress, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Plain Language Summary Financial toxicity is increasingly being recognized as an important and devastating consequence of cancer treatment that receives little attention when clinical trials are being designed. There is a significant need to obtain this important information in an era of increasingly expensive anticancer treatments. Patients who are informed of all implications of therapy—efficacy, side effects, cost, and broader financial impact—are able to select the best cancer treatment for themselves.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Northwestern University, Chicago, Illinois, USA.
- University of Michigan, Ann Arbor, Michigan, USA.
ORCID-Profile: Reshma Jagsi
Zitieren
APA
Gharzai, L. A., & Jagsi, R. (2023). Incorporating financial toxicity considerations into clinical trial design to facilitate patient‐centered decision‐making in oncology. Cancer. https://doi.org/10.1002/cncr.34677
Vancouver
Gharzai LA, Jagsi R. Incorporating financial toxicity considerations into clinical trial design to facilitate patient‐centered decision‐making in oncology. Cancer. 2023. doi:10.1002/cncr.34677
BibTeX
@article{Gharzai2023,
author = {Gharzai, Laila A and Jagsi, Reshma},
title = {Incorporating financial toxicity considerations into clinical trial design to facilitate patient‐centered decision‐making in oncology},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34677}
}
EUVIMED